About Symphony Medical
Symphony Medical is a biopharmaceutical company focused on non-destructive treatments for cardiac conduction abnormalities using cellular-based or biopolymer-based therapies.
Missing: Symphony Medical's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Symphony Medical's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Symphony Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Symphony Medical is included in 2 Expert Collections, including Advanced Materials.
Startups developing new or improved materials (chemicals, alloys, etc.) that provide physical or functional advantages to basic materials.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Symphony Medical Frequently Asked Questions (FAQ)
When was Symphony Medical founded?
Symphony Medical was founded in 2003.
Where is Symphony Medical's headquarters?
Symphony Medical's headquarters is located at 26051 Merit Circle, Laguna Hills.
What is Symphony Medical's latest funding round?
Symphony Medical's latest funding round is Series C.
How much did Symphony Medical raise?
Symphony Medical raised a total of $26.4M.
Who are the investors of Symphony Medical?
Investors of Symphony Medical include Morgenthaler Ventures, Domain Associates, Johnson & Johnson Innovation, Triathlon Medical Venture Partners and Guidant Compass Group.
Who are Symphony Medical's competitors?
Competitors of Symphony Medical include Animal Cell Therapies, CureDM, Sharklet Technologies, Dendreon, Celator Pharmaceuticals and 13 more.
Compare Symphony Medical to Competitors
Pivotal BioSciences, Inc. is a company focused on the development and commercialization of cancer therapies.
ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Effigene Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company developing small interference RNA (siRNA)-based therapeutics to treat various human diseases.
Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.
Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.